Log in to search using one of your social media accounts:


Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION

Treatment choice can be affected by patient comorbidities. Retrospective analysis of the phase 3 DASISION study suggested baseline comorbidities did not substantially affect 1-year safety and efficacy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Chronic Myelogenous Leukemia Source Type: research

Related Links:

More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Lymphoma | Men | Myeloma | Study